重组人脑利钠肽辅助治疗老年急性心力衰竭的临床疗效  

Clinical efficacy of recombinant human brain natriuretic peptide as an adjuvant therapy for elderly acute heart failure

作　　者：尤文军[1] 许彦倩 秦小杰[1] 赵培培 YOU Wenjun;XU Yanqian;QIN Xiaojie;ZHAO Peipei(Department of Geriatrics,Nantong Second People's Hospital,Nantong,Jiangsu,226002,China)

机构地区：[1]南通市第二人民医院老年医学科,江苏南通226002

出　　处：《当代医学》2023年第11期57-59,共3页Contemporary Medicine

摘　　要：目的探究重组人脑利钠肽辅助治疗老年急性心力衰竭的临床疗效。方法选取2019年3月至2020年2月本院收治的92例老年急性心力衰竭患者作为研究对象,随机分为对照组与观察组,各46例。对照组给予硝酸甘油治疗,观察组在对照组治疗基础上给予重组人脑利钠肽辅助治疗,比较两组治疗前后血压[舒张压(DBP)、收缩压(SBP)]、心率(HR)、生化指标[K^(+)、血肌酐(SCr)]及不良反应发生情况。结果治疗前,两组SBP、DBP及HR比较差异无统计学意义;治疗后,两组SBP、DBP、HR均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组K^(+)、SCr水平比较差异无统计学意义;治疗后,两组K^(+)水平均高于治疗前,SCr水平均低于治疗前,且观察组K^(+)高于对照组,SCr水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为4.35%,低于对照组的17.39%,差异有统计学意义(P<0.05)。结论在常规治疗的基础上予以重组人脑利钠肽辅助治疗老年急性心力衰竭可有效增强治疗效果,改善患者心力衰竭,临床应用价值较高。Objective To explore the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of elder acute heart failure.Methods 92 elderly patients with acute heart failure admitted to our hospital from March 2019 to February 2020 were selected as the study subjects,and they were randomly divided into the control group and the observation group,with 46 cases in each group.The control group was given nitroglycerin treatment,and the observation group was given recombinant human brain natriuretic peptide adjuvant treatment on the basis of the control group.The blood pressure(diastolic pressure[DBP],systolic blood pressure[SBP]),heart rate(HR),biochemical indexes(K^(+),blood creatinine[SCr])before and after treatment and adverse reactions were compared between the two groups.Results Before treatment,there were no significant differences in SBP,DBP and HR between the two groups;after treatment,the SBP,DBP and HR of two groups were lower than before treatment,and observation group was lower than control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in K^(+)and SCr levels between the two groups;after treatment,the levels of K^(+)of the two groups were higher than those before treatment,and the levels of SCr were lower than those before treatment,and the K^(+)level in the observation group was higher than that in the control group,and the SCr level was lower than that in the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 4.35%,which was lower than 17.39%in the control group,and the difference was statistically significant(P<0.05).Conclusion The adjuvant treatment of recombinant human brain natriuretic peptide on the basis of conventional treatment can effectively enhance the therapeutic effect,improve the heart failure,and have high clinical application value.

关 键 词：重组人脑利钠肽 老年急性心力衰竭 硝酸甘油 

分 类 号：R541.6[医药卫生—心血管疾病]